Exploring Treatment Approaches for High-Risk Myeloma and Response Durability

In this week's podcast we'll discuss another step forward in stamping out high-risk myeloma. Then we'll hear about the plasmin-cleaved von Willebrand factor, or VWF, in microthrombosis. Finally we'll hear about new insights into the origins of sickle cell pain. 

Featured Articles:

• Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly
  diagnosed myeloma
• Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis
• Sickle cell disease iPSC-derived sensory neurons exhibit increased excitability and sensitization to patient
  plasma